The role of COX-2 produced by cartilage in arthritis.
(49/3372)
The development of selective COX-2 inhibitors has renewed interest in the treatment of osteoarthritis with prostaglandin synthesis inhibitors. The therapeutic effects of COX inhibitors in OA may be due to their analgesic properties. However, it is now apparent that stable prostaglandins are produced by chondrocytes in OA cartilage where they may act to alter matrix synthesis and degradation. In vitro, PGEs activate metalloproteinases, but also enhance proteoglycan and type II collagen synthesis. Their net effect on matrix homeostasis in vivo remains to be determined. (+info)
Modulation of IL-1 effects on cartilage by NO synthase inhibitors: pharmacological studies in rats.
(50/3372)
Objective To compare the ability of L-arginine (L-arg) analog nitric oxide synthase (NOS) inhibitors and isothioureas to restore the interleukin-1 (IL-1) induced inhibition of proteoglycan (PG) synthesis in rat.Methods Chondrocytes beads and patellae were challenged with IL-1betain vitro and monitored for NO production and proteoglycan synthesis. Rats injected with IL-1beta in knee joints were monitored for NO(2)( - )+NO(3)( - )levels in joint tissues and ex-vivo(35)S sulfate incorporation in patellae. NOS inhibitors were either added to culture medium or injected concomittantly to IL-1beta. Results Ability of NOS inhibitors to reduce NO(2)( - )levels decreased from chondrocytes beads to patellae. Partial restoration of PG synthesis was restricted to L-arg analogs in patellae. After IL-1 injection, NO was produced from patella and synovium. L-arg analogs restored partly PG synthesis when decreasing significantly NO(2)( - )+NO(3)( - )levels in synovial fluid. Isothioureas were ineffective. Conclusions NO accounts importantly for IL-1 induced inhibition of cartilage anabolism in rat. L-arg analog NOS inhibitors are more effective than isothioureas in restoring PG synthesis and have chondroprotective potency when administered locally in diseased joint. (+info)
Phosphocitrate blocks nitric oxide-induced calcification of cartilage and chondrocyte-derived apoptotic bodies.
(51/3372)
OBJECTIVE: To examine whether phosphocitrate (PC) will block nitric oxide-induced calcification of cartilage or chondrocyte-derived apoptotic bodies. DESIGN: Articular cartilage vesicles (ACV) or apoptotic bodies (AB) were isolated from untreated or 1mM sodium nitroprusside (SNP) treated porcine cartilage slices. Mineralization of ACV, AB, control untreated and SNP-treated cartilage were done in the presence or absence of PC (1mM)+/-ATP (1mM). RESULTS: PC [1mM] blocked both the ATP-dependent and -independent mineralization in ACV and AB, untreated and SNP treated cartilage. Moreover, PC had no effect on NTPPPH activity in either ACV or AB fraction in the presence or absence of ATP suggesting that PC did not block the mineralization through the inhibition of NTPPPH activity. CONCLUSIONS: PC inhibits nitric oxide-induced calcification of cartilage and cartilage-derived apoptotic bodies. (+info)
Identification of aggrecanase activity in medium of cartilage culture.
(52/3372)
Erosion of cartilage is a major feature of joint diseases, i.e., osteoarthritis and rheumatoid arthritis, which leads with time to a loss of joint function. Proteolytic cleavage of the aggrecan core protein is a key event in the progress of these joint diseases. Aggrecan degradation has been believed to be mediated by a putative proteinase, aggrecanase. We identified aggrecanase activity in conditioned medium from explant culture of bovine nasal cartilage stimulated by retinoic acid. The activity was partially purified more than 10,000-fold. The enzyme cleaves at the aggrecanase site (Glu(373)-Ala(374)) but not at the MMP site (Asn(341)-Phe(342)) in the interglobular domain of the aggrecan. It also cleaves at Glu(1971)-Leu(1972), which is located in the gap region in the chondroitin sulfate attachment region prior to the aggrecanase site. The enzyme is a typical Ca(2+)-dependent metalloproteinase with a unique salt-dependency and is inhibited by several hydroxamate-based inhibitors for matrix metalloproteinases. Heparin and chondroitin sulfate inhibited the enzyme in a dose-dependent manner, suggesting that the large carbohydorate in aggrecan is important for substrate recognition by aggrecanase. (+info)
Characterization of recombinant human type IX collagen. Association of alpha chains into homotrimeric and heterotrimeric molecules.
(53/3372)
As type IX collagen is a minor cartilage component, it is difficult to purify sufficient amounts of it from tissues or cultured cells to study its structure and function. Also, the conventional pepsin digestion used for fibrillar collagens cannot be utilized for purifying type IX collagen, because it contains several interruptions in its collagenous triple helix. A baculovirus expression system was used here to produce recombinant human type IX collagen by coinfecting insect cells with three viruses containing full-length cDNAs for the alpha1(IX), alpha2(IX), and alpha3(IX) collagen chains together with a double promoter virus for the alpha and beta subunits of human prolyl 4-hydroxylase. Correctly folded recombinant type IX collagen was secreted, consisting of the three alpha chains in a 1:1:1 ratio and showing the expected biphasic thermal melting profile. When the individual alpha chains were expressed, disulfide-bonded homotrimers and homodimers of the alpha chains were observed. When the cells were coinfected with the viruses for all three alpha chains, heterotrimers of alpha1(IX), alpha2(IX), and alpha3(IX) were detected in cell culture medium, and the other possible combinations were less prominent. When any two of the alpha chains were co-expressed, in addition to the homodimers and homotrimers, only alpha1(IX) and alpha3(IX) chains were disulfide-bonded. The results thus suggest that the most favored molecular species is an alpha1(IX)alpha2(IX)alpha3(IX) heterotrimer, but the chains are also able to form disulfide-bonded heterotrimers of alpha1(IX) and alpha3(IX) chains and (alpha1(IX))(3), (alpha2(IX))(3), and (alpha3(IX))(3) homotrimers. (+info)
Parathyroid hormone-(1-34) enhances aggrecan synthesis via an insulin-like growth factor-I pathway.
(54/3372)
During endochondral bone formation, the growth plate chondrocytes proliferate, become hypertrophic, lose the cartilage phenotype, undergo mineralization, and provide a scaffold upon which subsequent longitudinal bone growth occurs. Parathyroid hormone (PTH), a calcium-regulating hormone, and parathyroid hormone-related peptide (PTHrP), which shares several properties with PTH, have profound effects on skeletal growth and new bone formation. In order to define further the mechanism by which PTH/PTHrP promotes the cartilage phenotype, chondrocytes isolated from the rib cages of developing rat embryos were evaluated for the biosynthesis of aggrecan. Cells treated with PTH-(1-34) for a 4-h period followed by a 20-h recovery period showed a significant increase in cartilage proteoglycan (aggrecan) synthesis in a dose-dependent manner. Only N-terminally intact PTH and PTHrP were effective in stimulating aggrecan synthesis. Addition of a neutralizing antibody to insulin-like growth factor-I (IGF-I) during PTH treatment resulted in the inhibition of PTH-stimulated aggrecan synthesis, whereas the addition of a neutralizing antibody to insulin-like growth factor-binding protein-2 (IGFBP-2) resulted in an increase in synthesis in both the control and PTH-treated cells. In addition, PTH treatment resulted in an increase in the mRNA for aggrecan, a reduction in IGFBP-3 mRNA, and no discernible changes in IGF-I mRNA levels, which was complemented by quantitative changes in IGFBP-3 and free IGF-I levels. The reciprocal relationship in the expression of aggrecan and IGFBP was further confirmed in chondrocytes from various gestational stages during normal development. Collectively, our results indicate that the effect of PTH may be mediated at least in part through the regulation of the IGF/IGFBP axis, by a decrease in the level of IGFBP-3, and an increase in free IGF-I levels. It is likely that the local increase in IGF-I may lead to an increase in cartilage type proteoglycan synthesis and maintenance of the cartilage phenotype. The consequence of the prolonged maintenance may be to halt mineralization while a new scaffolding is created. (+info)
Immunolocalisation of vascular endothelial growth factor (VEGF) in human neonatal growth plate cartilage.
(55/3372)
Angiogenesis is essential for the replacement of cartilage by bone during growth and repair. In order to obtain a better understanding of the mechanisms regulating vascular invasion at sites of endochondral ossification we have investigated the expression of the endothelial cell-specific mitogen, vascular endothelial growth factor (VEGF), by chondrocytes in human neonatal growth plates. VEGF was absent from chondrocytes in the resting zone and only weakly expressed by occasional chondrocytes in the proliferating region. In the hypertrophic zone the number of chondrocytes stained and the intensity of staining for VEGF increased with chondrocyte hypertrophy, maximum expression of VEGF being observed in chondrocytes in the lower hypertrophic and mineralised regions of the cartilage. These observations provide the first demonstration of the presence of VEGF in situ in developing human bone and are consistent with in vitro observations demonstrating the upregulation of proangiogenic growth factor production with increasing chondrocyte hypertrophy. The presence of numerous small blood vessels and vascular structures in the subchondral region where VEGF expression was maximal indicates that VEGF produced by hypertrophic chondrocytes may play a key role in the regulation of vascular invasion of the growth plate. (+info)
Generation of multiple transcripts from the chicken chondromodulin-I gene and their expression during embryonic development.
(56/3372)
Chondromodulin-I (ChM-I) is an angiogenesis inhibitor isolated from fetal bovine cartilage. Here, we report the nucleotide sequence of chicken ChM-I cDNA. Chicken mature ChM-I had a significantly larger N-terminal hydrophilic domain than its mammalian counterparts. Chicken embryos expressed multiple transcripts (3.3, 2.0 and 1.7 kb in size) due to the alternative utilization of polyadenylation signals, whereas only the 1.7 kb transcripts were detected in mammals. Although confined to cartilage and eye at a later stage of development, whole-mount in situ hybridization revealed the expression of ChM-I mRNA in somites, heart, bronchial arches, roof plate, retina and limb buds. The expression pattern of the gene suggests a role for ChM-I in the morphogenesis during embryonic development. (+info)